Auto Stem Cell Transplant for Lymphoma Patients
A legfontosabb adatok
- Ki végzi
- Masonic Cancer Center, University of Minnesota
- Hol
- Minneapolis (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 150 fő, tervezett
- Kezdés
- 2017. ápr. 20.
- Várható befejezés
- 2028. ápr. 30.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- Etoposide
- BCNU
- AraC
- Melphalan
- Peripheral blood stem cell transplantation
- G-CSF
- Cyclophosphamide
- Total Body Irradiation
- A regiszteradat frissítve
- 2026. november 4.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat Hodgkin- vagy non-Hodgkin-limfómás embereket keres, akik saját őssejtjeikkel végzett őssejt-átültetést kapnak. HIV-vel élők is csatlakozhatnak.
- Életkor
- Legfeljebb 75 év
- Nem
- Minden nem
- A betegség stádiuma
- Hodgkin-limfóma, amely visszatért, vagy nem reagált a korábbi kezelésre. Non-Hodgkin-limfóma, amely reagált a kemoterápiára; a remisszióra vonatkozó szabályok a limfóma típusától függnek.
- Korábbi kezelés
- Hodgkin-limfóma esetén a korábbi kezelés sikertelen volt. Az utolsó kemoterápia óta legalább 4 hétnek, a nitrozureák óta 6 hétnek kell eltelnie.
- Biomarker vagy leletérték
- HIV-vel élők csatlakozhatnak, ha HIV-kezelést kapnak, a CD4+ értékük legalább 50/µL, és a HIV RNS vírusterhelésük legfeljebb 100 000 kópia/mL. A hepatitis B hordozók is csatlakozhatnak.
A részvétel fő kizáró okai
- Terhesség vagy szoptatás
- Kemoterápiára nem reagáló limfóma
- Nagyobb prioritású másik átültetési protokollba is bevonható
- A limfómával nem összefüggő aktív fertőzés
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Eligible Diseases; Non-Hodgkin's Lymphoma (NHL); Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification; Patients in partial or complete remission following cell therapy will also be eligible; NHL patients with resistant or refractory lymphoma (no PR following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial; Lymphoblastic Lymphoma:; All patients will be eligible in second or greater complete remission (CR) or first or subsequent partial remission (PR); Patients with any high-risk features will be eligible in first complete remission; High risk features include: Stage IV, LDH >2 x upper limit of normal, ≥ 2 extranodal sites; Mature B-cell Lymphoma; Follicular Lymphoma and other indolent lymphoma in ≥ second CR2/PR2; Diffuse Large B-Cell Lymphoma: in ≥ CR2 or ≥ PR1; a high intermediate or high IPI (≥ 2 for age-adjusted IPI or ≥3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR; transformed lymphoma from FL (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative; Mantle Cell Lymphoma: in first or greater CR or PR; Burkitt's/Burkitt's like: all patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR; patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse; Mature T-Cell Lymphoma; Chemosensitive T-cell lymphomas including Primary T-cell not otherwise specified angioimmunoblastic, and ALK-positive anaplastic large cell, will be eligible after initial therapy, whether or not CR is achieved; Mycosis fungoides/Sezary syndrome will be eligible in ≥CR2/PR2; Hodgkin Lymphoma (HL); Patients with histologically proven HL will be eligible for transplantation after failing prior therapy; Patients with resistant disease (initial or at relapse): those who fail to achieve an objective partial response to three cycles of combination non-cross resistant chemotherapy will not be eligible for transplant in this trial; For stage I/II patients treated with primary chemotherapy-radiation, they must have failed (no CR or progression after CR) at least one salvage combination chemotherapy treatment regimen; For advanced (stage III/IV) Hodgkin disease, patients must have failed an Adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP); Patients with any high-risk features will also be eligible, including those who:; fail to achieve complete remission with initial combination chemotherapy; have bulky disease after initial therapy (chemotherapy or radiation) defined as residual mediastinal mass ≥ 5 cm or other residual mass ≥ 10 cm accompanied by other features of persisting disease (e.g., PET scan positive; high LDH; enlarging on serial x-rays or biopsy positive) will be eligible - if feasible, persistent disease should be proven by biopsy; Patients should receive chemotherapy to attempt to achieve CR or minimal disease state for all patients pre-transplantation. The use of up to three cycles of non-cross resistant combination chemotherapy is advised; Residual areas of limited disease should be considered for radiotherapy after and not prior to transplantation; HIV positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:; Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period; Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians. For the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor; CD4+ ≥ 50/µL; HIV RNA viral load ≤ 100,000 copies per mL on each of samples 4 weeks apart. The most recent level must be within 30 days of enrollment
- Performance Status: Karnofsky Performance Status ≥ 80% for patients ≥ 16 years of age or Lansky Play Score ≥ 80 for patients < 16 years of age. Note: if poor performance status is due to lymphoma - KPS ≥ 60% or LPS ≥ 60 is acceptable
- Organ Function; No evidence of serious organ dysfunction that is not attributable to tumor including:; Hematologic:; hemoglobin > 8 gm/dL; WBC > 2.5 x 109/L with an ANC > 1.5 x 109/L off G-CSF or GM-CSF for 10 days or Neulasta for 21 days; platelets > 100 x 109/L without transfusion; bone marrow cellularity of > 20% with <5% involvement with tumor; Renal: GFR > 50 ml/min/1.73m2 or serum creatinine ≤ 2.5 x ULN for age; Hepatic: no history of severe prior or ongoing chronic liver disease. Total bilirubin ≤ 2.0 mg/dl, AST and alkaline phosphatase <5x upper limit of normal; Cardiac: free of symptoms of uncontrolled cardiac disease including unstable angina, decompensated congestive heart failure, or arrhythmia. The ejection fraction by gated cardiac blood flow scan (MUGA) or Echocardiogram must be >40%; Pulmonary: no significant obstructive airways disease (FEV1 must be ≥ 50%) and must have acceptable diffusion capacity (corrected DLCO > 50% of predicted); Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment
- Other Inclusion Criteria; At least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas; Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment; Patients who are carriers of Hepatitis B will be included in this study; Voluntary written consent
Ki nem vehet részt
- Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
- Eligible for any higher priority transplant protocols
- Chemotherapy resistant disease
- Unrelated active infection
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Masonic Cancer Center, University of MinnesotaMinneapolis, Egyesült ÁllamokContact: Timothy KrepskiRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
A vizsgálat 3 csoportja
- BEAM: NHL & HLA vizsgált kezelés
BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
Kezelés: Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation és G-CSF
- CBV: HLA vizsgált kezelés
Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
Kezelés: Etoposide, BCNU és Cyclophosphamide
- CY/TBIA vizsgált kezelés
Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
Kezelés: Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide és Total Body Irradiation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2026. november 4.